Press release
Key Influencer in the Gastroesophageal Junction Adenocarcinoma Therapeutics Market 2025: Impact Of Growing Obesity Cases On The Market Driver
Gastroesophageal Junction Adenocarcinoma Therapeutics
The growing obesity cases are expected to propel the gastroesophageal junction adenocarcinoma therapeutics market. Obesity, driven by poor dietary habits, sedentary lifestyles, and other factors, is a significant risk factor for gastroesophageal junction adenocarcinoma (GEJA). This type of cancer, which often affects individuals with obesity, is linked to inflammation and metabolic disruptions that can exacerbate weight gain and disease progression. According to the World Health Organization in March 2024, 890 million adults worldwide were living with obesity, fueling the need for therapeutic solutions to manage GEJA in obese populations.
Get Your Gastroesophageal Junction Adenocarcinoma Therapeutics Market Report Here:
https://www.thebusinessresearchcompany.com/report/gastroesophageal-junction-adenocarcinoma-therapeutics-global-market-report
What is the projected compound annual growth rate (CAGR) of the gastroesophageal junction adenocarcinoma therapeutics market from 2025 to 2034, and what factors influence it?
The gastroesophageal junction adenocarcinoma therapeutics market has grown rapidly, increasing from $3.85 billion in 2024 to $4.48 billion in 2025 at a CAGR of 16.4%. Growth factors include the increasing prevalence of Helicobacter pylori infection, rising Barrett's esophagus cases, expanded screening programs, increased R&D investment, and improved healthcare access.
The gastroesophageal junction adenocarcinoma therapeutics market is anticipated to experience significant expansion, reaching $8.15 billion by 2029 at a CAGR of 16.1%. Growth drivers include the increasing focus on precision oncology, the rise of multidisciplinary treatment approaches, greater adoption of liquid biopsies, a shift toward minimally invasive procedures, and the growing use of immuno-oncology treatments. Notable trends include the integration of next-generation sequencing into clinical practice, innovations in targeted radiation therapy, advancements in molecular imaging, AI-driven treatment planning, and progress in surgical techniques.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21189&type=smp
How are the latest trends influencing the growth of the gastroesophageal junction adenocarcinoma therapeutics market?
Major companies operating in the gastroesophageal junction adenocarcinoma (GEJ) therapeutics market are advancing treatments like combination therapy to improve patient outcomes and combat resistance to current treatments. Combination therapy involves using two or more therapeutic agents together to increase their efficacy and target multiple aspects of a disease. In October 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, received FDA approval for zolbetuximab-clzb in combination with fluoropyrimidine- and platinum-containing chemotherapy. Zolbetuximab is a first-in-class monoclonal antibody that targets Claudin 18.2, a protein often expressed in gastric and GEJ cancers. By selectively binding to cancer cells expressing CLDN18.2, zolbetuximab enhances the precision of treatment, reducing damage to healthy tissues and improving therapeutic outcomes.
What are the major segments of the gastroesophageal junction adenocarcinoma therapeutics market and their role in driving growth?
The gastroesophageal junction adenocarcinoma therapeutics market covered in this report is segmented -
1) By Drug: Trastuzumab, Ramucirumab
2) By Diagnosis: Endoscopy, X-ray, Computed Tomography (CT) Scan, Positron Emission Tomography (PET) Scan
3) By Treatment: Esophagectomy Surgery, Esophageal Dilation, Chemotherapy, Targeted Therapy
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Trastuzumab: Monotherapy, Combination Therapy With Chemotherapy
2) By Ramucirumab: Monotherapy, Combination Therapy With Paclitaxel
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21189
Which regions are key players in the growth of the gastroesophageal junction adenocarcinoma therapeutics market?
North America was the largest region in the gastroesophageal junction adenocarcinoma therapeutics market in 2024. The regions covered in the gastroesophageal junction adenocarcinoma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Who are the key firms paving the way for growth in the gastroesophageal junction adenocarcinoma therapeutics market?
Major companies operating in the gastroesophageal junction adenocarcinoma therapeutics market are Pfizer Inc., F Hoffmann-La Roche AG, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Genentech Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., Zymeworks Inc., Zai Lab Limited, ImmunoGen Inc., Elevar Therapeutics Inc., Mirati Therapeutics Inc., Shanghai Henlius Biotech Inc., Taiho Pharmaceutical Co. Ltd., LintonPharm Ltd., Celltrion Healthcare Co. Ltd.
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21189&type=smp
What Is Covered In The Gastroesophageal Junction Adenocarcinoma Therapeutics Global Market Report?
•Market Size Forecast: Examine the gastroesophageal junction adenocarcinoma therapeutics market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the gastroesophageal junction adenocarcinoma therapeutics market for a structured understanding.
•Key Players Overview: Analyze major players in the gastroesophageal junction adenocarcinoma therapeutics market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the gastroesophageal junction adenocarcinoma therapeutics market.
•Segment Contributions: Evaluate how different segments drive overall growth in the gastroesophageal junction adenocarcinoma therapeutics market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the gastroesophageal junction adenocarcinoma therapeutics market.
•Industry Challenges: Identify potential risks and obstacles affecting the gastroesophageal junction adenocarcinoma therapeutics market.
•Competitive Landscape: Review strategic developments in the gastroesophageal junction adenocarcinoma therapeutics market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Key Influencer in the Gastroesophageal Junction Adenocarcinoma Therapeutics Market 2025: Impact Of Growing Obesity Cases On The Market Driver here
News-ID: 3935353 • Views: …
More Releases from The Business Research Company
Company Registration Service Market Landscape 2025: Forecast Data and Growth Str …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Company Registration Service Market Through 2025?
The market size for company registration services has seen robust growth in the recent past. The market is projected to expand from $10.67 billion in 2024 to $11.55 billion in 2025, exhibiting a compound annual growth…
Comprehensive 2025 Commercial Toilet Partition Market Overview: Trends, Forecast …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Commercial Toilet Partition Market Through 2025?
In recent years, the market size for commercial toilet partitions has significantly expanded. The forecast predicts a rise from $1.82 billion in 2024 to $1.95 billion in 2025, with a compound annual growth rate (CAGR) of…
Key Trends Influencing the Growth of the Commercial Insurance For Small And Medi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Commercial Insurance For Small And Medium-Sized Enterprises (SMEs) Market Through 2025?
The market size of commercial insurance for small and medium-sized enterprises (SMEs) has seen substantial growth over the recent years. A rise from $111.83 billion in 2024 to $119.76 billion in…
Growing Focus On Reducing Greenhouse Gas Emissions Driving The Market Growth Due …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Combustion Emissions Analyzer Market Through 2025?
In the past few years, the market size for combustion emissions analyzer has seen robust growth. It is projected to increase from $1.02 billion in 2024 to $1.09 billion in 2025, with a compound annual growth…
More Releases for Therapeutics
Adrenomyeloneuropathy Market: Epidemiology, Therapies, Companies, DelveInsight | …
Adrenomyeloneuropathy emerging therapies are expected to boost the Adrenomyeloneuropathy Market in the upcoming years.
DelveInsight has launched a new report on "Adrenomyeloneuropathy - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Adrenomyeloneuropathy, historical and forecasted epidemiology as well as the Adrenomyeloneuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover about the Adrenomyeloneuropathy market report @ https://www.delveinsight.com/report-store/adrenomyeloneuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Some of the…
Pompe Disease Market: Epidemiology, Therapies, Companies, DelveInsight | Genzyme …
Pompe Disease emerging therapies, such as MYOZYME (alglucosidase alfa), LUMIZYME, AAV2/8-LSPhGAA, Avalglucosidase alfa, and others, are expected to boost the Pompe Disease Market in the upcoming years.
DelveInsight has launched a new report on "Pompe Disease - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Pompe Disease, historical and forecasted epidemiology as well as the Pompe Disease market trends in the United States, EU5 (Germany, Spain,…
Dark Genome Therapeutics Market Deep Research Report with Forecast to 2032 | myN …
The qualitative latest Research report (2025-2032) on the Dark Genome Therapeutics Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves.
Request a Sample Copy: https://www.coherentmarketresearch.com/samplepages/133611
Focused on growth…
Hodgkin's lymphoma Therapeutics Market Size Report 2032 | Affimed Therapeutics, …
DelveInsight's "Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Hodgkin's Lymphoma, historical and forecasted epidemiology as well as the Hodgkin's Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United kingdom and Japan.
Discover Key Insights into the Hodgkin's lymphoma Market with DelveInsight's In-Depth Report @ Hodgkin's lymphoma Market Size- https://www.delveinsight.com/sample-request/hodgkins-lymphoma-hl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Hodgkin's…
CRISPR Therapies Pipeline 2024 | Intellia Therapeutics, CRISPR therapeutics, Rep …
DelveInsight's, "CRISPR Therapies Pipeline Insight 2024" report provides comprehensive insights about 25+ CRISPR Therapies Companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR Therapies pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CRISPR Therapies therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive CRISPR Therapies pipeline products in this space.
Key Takeaways from…
Digital Therapeutics Market, Digital Therapeutics Market Size, Digital Therapeut …
The global digital therapeutics market is expected to reach US$ 8,941.1 Mn by 2025 from US$ 1,993.2 Mn in 2017. The market is estimated to grow with a CAGR of 20.8% during the forecast period from 2018 to 2025.
North America is the largest geographic market and it is expected to be the largest revenue generator during the forecast period, whereas the market is expected to witness growth at a significant…
